Neurodegenerative Disorders Therapeutics
1. Amyvid patent expiration
Treatment: Pet to estimate amyloid beta neuritic plaque density in adults with cognitive impairment: -evaluation of alzheimer’s disease and other causes of cognitive decline -selection of patients who are indica...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8506929 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(1 year, 3 months from now) | |
| US7687052 | AVID RADIOPHARMS INC | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques |
Apr, 2027
(1 year, 3 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2017 |
Drugs and Companies using FLORBETAPIR F-18 ingredient
NCE-1 date: 06 April, 2016
Market Authorisation Date: 06 April, 2012
Dosage: SOLUTION
More Information on Dosage
AMYVID family patents
2. Namenda patent expiration
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5061703 (Pediatric) | ALLERGAN | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(10 years ago) | |
| US5061703 | ALLERGAN | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(10 years ago) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 18 April, 2005
Dosage: SOLUTION
How can I launch a generic of NAMENDA before it's drug patent expiration?
More Information on Dosage
NAMENDA family patents
3. Namenda patent
expiration
Treatment: Treatment of moderate to severe dementia of the alzheimer's type
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5061703 (Pediatric) | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(10 years ago) | |
| US5061703 | ABBVIE | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(10 years ago) | |
Drugs and Companies using MEMANTINE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 October, 2003
Dosage: TABLET
How can I launch a generic of NAMENDA before it's drug patent expiration?
More Information on Dosage
NAMENDA family patents
4. Skyclarys patent expiration
Treatment: Method of treating friedrich's ataxia by activating the nrf2 pathway which reduces oxidative stress; Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9701709 | BIOGEN US | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(7 years from now) | |
| US9670147 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| US8993640 | BIOGEN US | 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof |
Apr, 2033
(7 years from now) | |
| US8124799 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11919838 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| US11091430 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 |
Apr, 2029
(3 years from now) | |
| US8440854 | BIOGEN US | Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17 |
Apr, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-270) | Dec 20, 2027 |
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2028 |
| Orphan Drug Exclusivity(ODE-427) | Feb 28, 2030 |
Drugs and Companies using OMAVELOXOLONE ingredient
NCE-1 date: 28 February, 2027
Market Authorisation Date: 28 February, 2023
Dosage: CAPSULE
More Information on Dosage
SKYCLARYS family patents
5. Spinraza patent expiration
Treatment: Treatment of spinal muscular atrophy by increasing exon-7 inclusion in smn2 mrna; Treatment of spinal muscular atrophy; Treatment of type iii spinal muscular atrophy; Treatment of infantile-onset spin...
SPINRAZA's oppositions filed in EPO
Can you believe SPINRAZA received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6166197 | BIOGEN IDEC | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
Dec, 2017
(8 years ago) | |
| US7101993 | BIOGEN IDEC | Oligonucleotides containing 2′-O-modified purines |
Sep, 2023
(2 years ago) | |
| US8361977 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing |
Dec, 2030
(4 years from now) | |
| US7838657 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Jul, 2027
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6210892 | BIOGEN IDEC | Alteration of cellular behavior by antisense modulation of mRNA processing |
Oct, 2018
(7 years ago) | |
| US9926559 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jan, 2034
(8 years from now) | |
| US9717750 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Jun, 2030
(4 years from now) | |
| US8110560 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(a month ago) | |
| US10436802 | BIOGEN IDEC | Methods for treating spinal muscular atrophy |
Sep, 2035
(9 years from now) | |
| US12013403 | BIOGEN IDEC | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
Mar, 2036
(10 years from now) | |
| US8980853 | BIOGEN IDEC | Compositions and methods for modulation of SMN2 splicing in a subject |
Nov, 2030
(4 years from now) | |
| US10266822 | BIOGEN IDEC | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
Dec, 2025
(a month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-226) | May 14, 2021 |
| New Chemical Entity Exclusivity(NCE) | Dec 23, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 23, 2023 |
| Orphan Drug Exclusivity(ODE-127) | Dec 23, 2023 |
Drugs and Companies using NUSINERSEN SODIUM ingredient
NCE-1 date: 23 December, 2020
Market Authorisation Date: 23 December, 2016
Dosage: SOLUTION
More Information on Dosage
SPINRAZA family patents